GlassScriptPhysician profile
Paul J Robinson
NPI 1750389698
$10,419.58
in general payments reported to CMS, 2019-2025
40 companies · $922 in 2025
The $922 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,901 · 2020: $1,823 · 2021: $2,043 · 2022: $1,164 · 2023: $1,524 · 2024: $1,041 · 2025: $922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,487.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,569.36 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $1,198.01 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $1,055.26 | 2019-2024 | Xarelto |
| Amgen INC. | $961.12 | 2019-2025 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $749.98 | 2021-2025 | |
| Pfizer INC. | $702.68 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $692.36 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novartis Pharmaceuticals Corporation | $486.13 | 2019-2023 | |
| Lilly USA, LLC | $322.77 | 2019-2025 | Jardiance, Mounjaro |
| Amarin Pharma, INC. | $276.12 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $233.20 | 2020-2021 | |
| Glaxosmithkline, LLC. | $221.63 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $208.96 | 2021-2023 | Xifaxan |
| Boston Scientific Corporation | $201.64 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $200.52 | 2019-2020 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.